key: cord-0895845-vkkgpwid authors: Xu, Xin; Nie, Sheng; Sun, Jian; Kong, Yaozhong; Liang, Min; Li, Dongfeng; Ma, Tean; Peng, Jiaqing; Gao, Shikui; Shao, Yong; Zha, Yan; Peng, Gangyi; Ren, Chanjun; Huang, Ailong; Hou, Fan Fan title: The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients date: 2020-07-18 journal: Kidney Int Rep DOI: 10.1016/j.ekir.2020.07.010 sha: 092d213981ee20165fc4f4175a1f6ed70840f490 doc_id: 895845 cord_uid: vkkgpwid BACKGROUND: There is a paucity of information regarding SARS-CoV-2 infection in patients undergoing maintenance hemodialysis. We aimed to estimate the cumulative attack rate of SARS-CoV-2 in hemodialysis patients in China using a serological test. METHOD: We enrolled all hemodialysis patients from 8 hemodialysis facilities in Honghu and Jingzhou of Huibei province and Guangzhou and Foshan of Guangdong province in China. We screened these patients for SARS-CoV-2 infection by both a RT–PCR test for viral RNA and a serological test for IgG and IgM antibodies. Data on demographics and clinical characteristics were collected via case report forms. We also enrolled the healthcare workers (HCWs) from the participating hospitals and compared the seropositive rate between hemodialysis patients and HCWs in the same region. RESULT: Among 1,542 hemodialysis patients, 5 (0.32%) and 51 (3.3%) were tested positive by the RT-PCR test and the serological test, respectively. The seropositive rate in Hubei (3.6%) was higher than that in Guangdong (2.8%), though the difference was not statistically significant (p=0.5). Most of the seropositive patients were asymptomatic. Older than 65 years, having manifestation of lung infection in imaging examines, and lower level of serum albumin were independent risk factors for SARS-CoV-2 infection. In comparison, the seropositive rate in 3,205 HCWs was 1.2% which was significantly lower than that observed in the hemodialysis patients (p<0.001). CONCLUSION: The cumulative rate of SARS-CoV-2 infection in hemodialysis patients in China was high at 3.3%. Serological test detected 10 times more cases of SARS-CoV-2 infection than the RT-PCR test and should be the preferred tool for estimating the prevalence of COVID-19. Novel coronavirus disease 2019 (COVID-19) is a highly contagious disease caused by SARS-CoV-2 1-3 . The World Health Organization has declared it a global pandemic on March 12, 2020 4 . As of June 6, 2020, about 6.8 million cases of COVID-19 have been reported in 188 countries with nearly 400,000 deaths. 5 COVID-19 has been reported in all ages, including children. 6 Pregnant women, the elderly, and patients with comorbidities are more susceptible to the infection and are likely to experience severer illness. 7 Patients with end-stage kidney disease (ESKD), particularly those on in-facility hemodialysis, present a potential risk for COVID-19. Patients on HD are characterized by dysfunction in both innate and adaptive immune system which predisposes them to an increased risk of infections and a diminished vaccine response. 8 To date, there is a paucity of information regarding SARS-CoV-2 infection in patients undergoing maintenance hemodialysis. Detection of SARS-CoV-2 from asymptomatic subjects 9, 10 suggests that subclinical SARS-CoV-2 infection is possible and could be seeding new outbreaks. Currently, the reported cases of COVID-19 are those with clinical symptoms, in close contact with the confirmed cases, or with history of travel to the epidemic regions, and relies on a RT-PCR test that is sensitive to the method and the timing of specimen collection 6, 7 . A large number of subclinical infection cases are believed to be undetected. Therefore, it is crucial to assess the rates of subclinical SARS-CoV-2 infection, particularly in vulnerable populations, and to understand their infectivity and future immunity to COVID-19. 11, 12 The serological test for antibodies against SARS-CoV-2 should provide a more accurate assessment on the scope of COVID-19 epidemic in a population compared with the RT-PCR test. However, the serological test has not been available until very recently. We conducted a screening survey on SARS-CoV-2 infection in patients from 8 hemodialysis facilities in two cities (Jingzhou and Honghu, Hubei province) close to Wuhan, the epicenter of China, and another two cities (Guangzhou and Foshan, Guangdong province) far from the epicenter. The aim of the study is to estimate the cumulative rates of SARS-CoV-2 infection detected by both the RT-PCR test and the serological test in patients on maintenance hemodialysis and compare with that in healthcare workers in the same regions. The Medical Ethics Committee of Nanfang Hospital approved the study. All patients signed a consent form. Laboratory measurements. Nasopharyngeal swabs of the hemodialysis patients were collected by trained nurses in local facility, and tested for SARS-CoV-2 RNA in a designated virology laboratory in the region using the real-time RT-PCR assay as previously reported 18 . The test results were further confirmed by local CDC. Serum samples were collected in local facilities. All samples were inactivated at 56 °C for 30 min and stored at -20 °C before testing. The IgG and IgM antibodies against SARS-CoV-2 were measured at a central laboratory (Kingmed Diagnostic Center, China) using a commercially available Magnetic Chemiluminescence Enzyme Immunoassay kit (Bioscience, Chongqing, China) according to the manufacturer's instructions 13 . Antibody levels were expressed as the ratio of the chemiluminescence signal over the cutoff value (S/CO). A S/CO value of >1.0 for either IgG or IgM was regarded as positive. We independently validated the serological assay using sera of 447 ESKD/HD patients collected before June 2019 as a negative control and sera of 242 COVID-19 patients confirmed by the viral nucleic acid test as a positive control. 19 In the validation, the serological test had an overall sensitivity of 83% and specificity of 100%. In patients with confirmed COVID-19, the cumulative seropositive rates of IgG and IgM were 56% and 44%, respectively, on the 7 th day after the onset of symptoms, and reached 95% on the 16 th day and the 20 th day, respectively. Both IgG and IgM levels can persist for at least 28 days. Statistical analysis. Among 1,567 hemodialysis patients enrolled, 25 missed the case report forms and were excluded from further analyses. Clinical characteristics of the patients were summarized by strata of seropositive status. Continuous variables were presented as mean ± standard deviation (SD), and categorical variables as counts and percentages. A single logistic regression model was use to estimate the effects of age, gender, region, comorbidities, symptoms, CT findings and laboratory tests on the risk of being seropositive. In the regression, missing values were assigned to the modal category. The difference between groups was tested using the Mann-Whitney method for quantitative variables and a Chi-square test for categorical variables. In validation of the serological assays, the cumulative rates of seropositive for IgG and IgM after the onset of symptoms were estimated using the Kaplan-Meier method in COVID-19 patients. A total of 1,542 patients, constituted of >98% of the patients on maintenance hemodialysis in the participating facilities, were screened by both a RT-PCR test with a nasopharyngeal swab and a serological assay of IgG and IgM antibodies to recombinant antigen of SARS-CoV-2. 13 The RT-PCR tests were performed between January 21 st and March 8 th , while serological tests were performed between March 1 st and 15 th , 2020. Among the hemodialysis patients in Hubei and Guangdong, 5 (0.5%) and 0 (0%) were tested positive for viral RNA (Table 1) Table 2 . Over 95% of all serology-positive patients were without any symptoms. Serology-positive patients were on average 8 years older than serology-negative ones and were more likely to have manifestations of lung infection in chest computerized tomography (CT) and lower level of serum albumin (P<0.01 for all). Otherwise, the two groups shared similar clinical features, including the etiology of ESKD, presence of comorbidities, and the counts of leukocytes and lymphocytes. Although the observed infection rate in the patients from Hubei seemed to be higher than that from Guangdong, the differences were not statistically significant (P=0.5). In our regression analysis, older than 65 years, having manifestation of lung infection in imaging examines, and lower serum albumin were independent risk factors for SARS-CoV-2 infection, with corresponding odds ratios (95% confidence intervals) of 2.17 (1.22, 3.87), 2.96 (1.65, 5.33), and 3.37 (1.53, 7.40), respectively (Table 3) . As a comparison, the seropositive rate was 1.2% (36/2,945) and 1.2% (3/260) among healthcare workers in Hubei and Guangzhou, respectively. When pooled over the regions, the seropositive rate in the hemodialysis patients was significantly higher than that observed in healthcare workers in the same regions (p<0.001) (Figure 1 ). To the best of our knowledge, this is the first multicenter survey to estimate the rates of SARS- healthcare workers. In the hemodialysis population, the positive rate detected by the serological antibody test was high at 3.3% compared to 0.32% detected by the RT-PCR test. More than 90% of the infection detected by the serological test were missed by the RT-PCR test, highlighting the inefficiency of the RT- Herd immunity has been proposed as a strategy for prevention and control of future SARS-CoV-2 infection and outbreak, which is predicted to occur when two third of the population are infected. Our current study populations do not cover the most severe epidemic regions such as Wuhan, and the current cumulative infection rates from our study are lower than that reported in New York city 15 and far lower than the two-thirds population threshold for herb immunity. Due to the cross-sectional design of the current study, we are not able to monitor the dynamic changes of antibody titer in the infected patients. It would be of importance to know how long the antibodies persist in an individual and the quantitative titer of antibodies in an asymptomatic patient that may provide immunity against future infections. In our hemodialysis population, manifestation of lung infection in imaging studies is an independent predictor for SARS-CoV-2 infection. However, more than 30% of the seronegative patients who received chest CT also had manifestation of lung infection, including ground-glass opacity, suggesting that such imaging features are not specific markers for SARS-CoV-2 infection. The prevalence of COVID-19 confirmed by the RT-PCR test in our dialysis population in Hubei (5 out of 978) was at least an order of magnitude higher than that reported in the general populations from the same regions, which was 2.5 per 10,000. 16 This difference may partly be explained by the limited and selective testing in the general population, which results in substantial underestimation of the disease prevalence. 17 In our study, the cumulative rates of SARS-CoV-2 infection in hemodialysis patients was higher than that in healthcare workers from the same regions. This may be attributable to multiple factors. First, hemodialysis population is elder than that of healthcare workers. Second, hemodialysis patients have to visit the dialysis facilities regularly even if an infection has been suspected. Thus, the hemodialysis facilities may become a cespool environment similar to nursing home facilities. Third, compared with healthcare workers, dialysis patients may have a lower level of personal protection. Finally, dialysis patients may be more susceptible to SARC-CoV-2 infection due to acquired immunodeficiency. Good management of hemodialysis patients during the epidemic requires aggressive testing in hemodialysis patients, early isolation of the patients suspected of infection, intensive disinfection of the dialysis equipment, and adequate personal protection in both healthcare workers and the patients. Our study is subject to several limitations. First, the relatively small number of seropositive cases prevented us from a more detailed analysis among subgroups. Second, the serological tests were performed at local laboratories using different assay kits. However, all these kits were approved by the National Medical Products Administration of China. Third, the sensitivity of the serological test depends on the timing, the level, and the duration of antibody production after SARS-CoV-2 infection. Testing too soon (before the start of antibody production) or too late (after the stop of antibody production) or in individuals with immunodeficiency may produce false negative result. For this reason, the serological test may under-estimate the prevalence of SARS-CoV-2 infection. In summary, we estimated a cumulative rate of 3.6%, and 2.8% for SARS-CoV-2 infection in hemodialysis patients in Hubei and Guangdong, respectively. Serological test detected 10 times more cases of SARS-CoV-2 infection than the RT-PCR test and should be the preferred tool for estimating the prevalence of COVID-19. The authors declare no competing interests. Signs of lung infection on CT included ground-glass opacity, local or bilateral patchy shadowing. Symptoms included fever, cough, sputum, and dyspnea. For some clinical features, the sample size of all subgroups may not sum up to the total sample size due to missing value. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan A Novel Coronavirus from Patients with Pneumonia in China Director-General's opening remarks at the media briefing on COVID-19-11 Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Immune Dysfunction and Risk of Infection in Chronic Kidney Disease Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 Infection in Children Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing World Health Organization, Global surveillance for COVID-19 disease caused by human infection with the 2019 novel coronavirus A Novel Coronavirus Emerging in China -Key Questions for Impact Assessment Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany New York antibody study estimates 13.9% of residents have had the coronavirus Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China Guangdong laboratory (to Dr. Hou). The data used and analyzed during the current study are available from the corresponding author on reasonable request.